Specialty Pharmacy

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

Medication will be used as an add-on maintenance therapy in patients aged 12 years and older.

Caregivers can have trouble differentiating ulcerative colitis from Crohn's disease and inflammatory bowel disease.

Pharmacists in Washington State can no longer cite religion to refuse to fill a prescription.

Diabetics are at greater risk for viral and bacterial infection compared with the remainder of the population.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

Study finds significant barriers to health care access, including stigmatization.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Oxygen therapy use spikes since 2000.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Studies show inexpensive, generic drugs can help reduce breast cancer mortality in postmenopausal women.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Top stories of the week on Specialty Pharmacy Times.

Compound shows promise in reducing a precursor to RA.

Lithium chloride found to slow degradation.

Algorithm uses a computational model of the human body's protein networks.

Finacea Foam showed a greater reduction in the average nominal change of inflammatory lesion count.

Up to 13% of patients considered to have chronic obstructive pulmonary disease (COPD) under current criteria were recently found to be misdiagnosed.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

Liver damage progresses at a more rapid pace in patients with HIV.

Long-term survival results after 5 years of ipilimumab therapy in patients with advanced melanoma shows promise.

Researchers evaluate solutions to quality-of-life issues.

Galena Biopharma had introduced ondansetron (Zuplenz) to the US market.

Sofosbuvir-based therapy offers the potential for high cure rates even in difficult-to-treat patient groups.

Toradol may limit ability of tumor cells to grow and spread.

Toxin may inhibit cell division in cancerous cells.

Generic Pulmicort Respules is approved for the treatment of asthma and to serve as prophylactic therapy in children aged 12 months to 8 years.

Study finds 80% of people with cardiovascular disease significantly underuse statins.